Diagnostic system strengthening for drug resistant tuberculosis in Nigeria: impact and challenges
| Autor: | Mosunmola Iwakun, Nicholas Ezati, Samuel Peters, Alash'le Abimiku, Gambo Aliyu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Tuberculosis 030106 microbiology Clinical Biochemistry Nigeria Drug resistance Diagnostic system 03 medical and health sciences Biosafety Acquired immunodeficiency syndrome (AIDS) Biosafety level medicine BSL 3 laboratory Drug-resistant tuberculosis business.industry Drug resistant tuberculosis Public health lcsh:Public aspects of medicine Public Health Environmental and Occupational Health lcsh:RA1-1270 medicine.disease Surgery Medical Laboratory Technology Lessons from the Field Medical emergency business |
| Zdroj: | African Journal of Laboratory Medicine, Vol 6, Iss 2, Pp e1-e6 (2017) African Journal of Laboratory Medicine, Volume: 6, Issue: 2, Pages: 1-6, Published: 2017 African Journal of Laboratory Medicine |
| ISSN: | 2225-2010 2225-2002 |
| Popis: | Background: The increasing prevalence of drug-resistant tuberculosis and the threat of extensively-drug-resistant tuberculosis in HIV hotspots have made the detection and treatment of drug-resistant tuberculosis in the sub-Saharan Africa setting a global public health priority. Objective: We sought to examine the impact and challenges of tuberculosis diagnostic capacity development for the detection of drug-resistant tuberculosis and bio-surveillance using a modular biosafety level 3 (BSL-3) laboratory in Nigeria. Method: In 2010, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) programme, through the Institute of Human Virology at the University of Maryland in Baltimore, Maryland, United States, deployed a modular, BSL-3 laboratory to support the national tuberculosis programme in drug-resistant tuberculosis detection and bio-surveillance for effective tuberculosis prevention and control. Results: From 2010 until present, sputum samples from 11 606 suspected cases in 33 states were screened for drug-resistant tuberculosis. Of those, 1500 (12.9%) had mono-resistant tuberculosis strains, and 459 (4.0%) cases had multidrug-resistant tuberculosis. Over the lastfour years, 133 scientists were trained in a train-the-trainer programme on advanced tuberculosis culture, drug susceptibility testing, line-probe assays and Xpert® MTB/RIF, in addition to safety operations for biosafety facilities. Power instability, running cost and seasonal dust are notable challenges to optimal performance and scale up. Conclusion: Movable BSL-3 containment laboratories can be deployed to improve diagnostic capacity for drug-resistant tuberculosis and bio-surveillance in settings with limited resources. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|